Pharmacokinetic Analysis and Antiepileptic Activity of Tetra-Methylcyclopropane Analogues of Valpromide

Pharmaceutical Research

Volumn 13, Issue 2, 1996, Pages 284-289

  Bialer, Meir ^a   Hadad, Salim ^a   Kadry, Bashier ^a   Abdul Hai, Ali ^a   Haj Yehia, Abdulla ^a   Sterling, Jeff ^b   Herzig, Yaacov ^b   Yagen, Boris ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

Antiepileptic activity; Pharmacokinetics; Structural requirements; Tetramethylcyclopropane derivatives; Valproic acid; Valpromide

Indexed keywords

ANTICONVULSIVE AGENT; CYCLOPROPANE DERIVATIVE; VALPROIC ACID; VALPROIC ACID DERIVATIVE; VALPROMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; ANTICONVULSANTS; CYCLOPROPANES; DOGS; DRUG STABILITY; HYDROLYSIS; MICE; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 0030052508     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016055517724     Document Type: Article

References (23)

1. M. Bialer. Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20:114-122 (1991).
2. A. Haj-Yehia, S. Hadad and M. Bialer. Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide. Pharm. Res. 9:1058-1063 (1992).
3. A. Haj-Yehia and M. Bialer. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharm. Res. 6:682-689 (1989).
4. A. Haj-Yehia and M. Bialer. Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 79:719-724 (1990).
5. R. H. Levy and P. D. Shen. Valproate: absorption, distribution and excretion. In R. H. Levy, R. H. Mattson and B. S. Meldrum (eds) Antiepileptic Drugs, 4th ed. Raven Press, 1995, pp. 605-620 and other chapters on valproate therein.
6. M. Bialer, A. Haj-Yehia, K. Badir and S. Hadad. Can we develop improved derivatives of valproic acid? Pharm. World Sci. 16:2-6 (1994).
7. H. Nau and A. G. Hendrickx. Valproic acid teratogenesis. ISI Atlas Sci. Pharmacol. 52-56 (1987).
8. H. Nau, E. S. Hauck and K. Ehlers. Valproic acid induced neural tube defects in mouse and humans: apsects of chirality, alternative drug development, pharmacokinetics and possible mechanism. Pharmacol. Toxicol. 69:310-321 (1991).
9. R. H. Levy and J. K. Penry. Idiosyncratic reactions to valproate: clinical risk patterns and mechanism of toxicity. Raven Press, 1991.
10. St. A. Konig, H. Siemes, F. Blaker, E. Boenigk, G. Grop-Selbeck, F. Hanefeld, N. Haas, B. Kohler, W. Koelfen, R Krointhenberg, E. Kurek, H. G. Lenard, H. Penin, J. M. Penzien, W. Schumke, C. Schultze, U. Stephan, M. Stute, M. Traus, H. M. Weinmann and D. Scheffner. Severe hepatotoxicity during valproate therapy: An update and report of eight new fatalities. Epilepsia 35:1005-1015 (1994).
11. H. J. Zimmerman and K. Ishak. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2:591-597 (1992).
12. E. S. Zafrani and P. Berthelot. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 2:648-649 (1982).
13. R. J. Porter, J. J. Ceregino, G. D. Gladding, B. J. Hessie, H. J. Kupferberg, B. Scoville and B. G. White. Antiepileptic drug development program. Cliv. Clin. Q. 51:293-305 (1984).
14. S. Hadad and M. Bialer. Pharmacokinetic analysis and antiepileptic activity of new valproyl derivatives of GABA and glycine. Pharm. Res. 12:905-910 (1995).
15. M. Bialer, M. Friedman and J. Dubrovsky. A rapid GLC assay for monitoring valproic acid and valpromide in plasma. J. Pharm. Sci. 73:991-993 (1984).
16. M. Bialer and B. Hoch. Rapid gas chromatographic assay for monitoring valnoctamide in plasma. J. Chromatogr. Biomed. Appl. 337:408-411 (1985).
17. M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, pp 445-449.
18. L. S. Benet and R. L. Galeazzi. Noncompartmental determination of steady-state volume of distribution. J. Pharm. Sci. 68:1071-1074 (1979).
19. K. Yamaoka, T. Nakagawa and T. Uno. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:547-558 (1977).
20. K. Yamaoka. Methods for pharmacokinetic analysis for personal computer, 2nd ed., Nanko-D, Tokyo, 1986, pp. 145-175.
21. V. Nadler, Y. Kloog and M. Sokolovsky. 1-Aminocyclopropane-1-carboxylic acid (ACC) mimics the effects of glycine in the NMDA receptor ion channel. Eur. J. Pharmacol. 157:115-116 (1988).
22. R. Trullas, T. Folio, A. Young, R. Miller, K. Boje and P. Skolnik. 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur. J. Pharmacol. 203:379-385 (1991).
23. M. Bialer and A. Rubinstein. A comparative study in the pharmacokinetics of valpromide after i.v. administration in dogs. J. Pharm. Pharamacol. 38:607-609 (1983).